3 Chronic Therapy Brands Company, Domestic Acute Care Leader and Active Ingredients Producer Stocks With a Strong Future Roadmap: Eris Lifesciences, Alkem Laboratories and Granules India
- October 26, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Eris Lifesciences, Alkem Laboratories and Granules India: ROE of 11.7% to 16.7% and FY22 to FY26 revenue CAGR of 9.1% to 22.9%. Prices as of 23 Oct 2026.
Quick Answer
The three chronic, acute care and ingredient pharma stocks to watch are Eris Lifesciences, Alkem Laboratories and Granules India. Their return on equity ranges from 11.7% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 22.9%. Alkem Laboratories has the highest return on equity at 16.7%, while Eris Lifesciences has the fastest revenue growth at 22.9% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Chronic, acute care and ingredient pharma stocks let investors follow companies that serve a growing part of the Indian economy. Eris Lifesciences, Alkem Laboratories and Granules India cover a chronic therapy brands company, a domestic acute care leader and an active ingredients producer.
This list covers three chronic, acute care and ingredient pharma stocks with complete current figures: Eris Lifesciences, Alkem Laboratories and Granules India. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Chronic, Acute Care and Ingredient Pharma Stocks?
Chronic, acute care and ingredient pharma stocks are listed drug makers that sell chronic and acute care brands in India and supply formulations and ingredients overseas. Their earnings depend on prescriptions, launches, plant quality and export demand.
Chronic, Acute Care and Ingredient Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Eris Lifesciences | 1,095.5 | 15,618 | 23.5 | 36.0 | 15.9 | 0.60 |
| Alkem Laboratories | 4,947 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
| Granules India | 794.75 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing chronic, acute care and ingredient pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in chronic, acute care and ingredient pharma stocks can use the coming numbers to test whether growth is holding.
Why Do Chronic, Acute Care and Ingredient Pharma Stocks Have a Strong Roadmap in India?
Chronic, acute care and ingredient pharma stocks have a strong roadmap in India because growing healthcare access, longer treatment spans and global sourcing of ingredients keep lifting the revenue base.
- Chronic therapies. Long-term treatments give repeat demand.
- Acute care brands. Trusted brands win doctor preference.
- Ingredient volumes. High-volume molecules support steady output.
Why Eris Lifesciences Features Among These Chronic, Acute Care and Ingredient Pharma Stocks
Among the chronic, acute care and ingredient pharma stocks on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.
Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%.
In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.
Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.
Why Alkem Laboratories Features Among These Chronic, Acute Care and Ingredient Pharma Stocks
Among the lifestyle disease brand shares on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.
Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
Why Granules India Features Among These Chronic, Acute Care and Ingredient Pharma Stocks
Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Eris Lifesciences vs Alkem Laboratories vs Granules India on Key Financials
The table below sets the three chronic, acute care and ingredient pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Eris Lifesciences | 1,373 | 3,137 | 22.9% | 648 | 20.6% |
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
Alkem Laboratories posts the highest return on equity in this group at 16.7%. Alkem Laboratories has the largest FY26 revenue at Rs 15,296 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with chronic, acute care and ingredient pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Eris Lifesciences | 776 | 876 | 12.9% |
| Alkem Laboratories | 3,508 | 3,893 | 11.0% |
| Granules India | 1,226 | 1,479 | 20.6% |
Key Risks to Check Before Investing in Chronic, Acute Care and Ingredient Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these chronic, acute care and ingredient pharma stocks, the main points are: Long-term lifestyle disease brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices can fall in some markets.
- Input costs. Solvent and raw material prices affect margins.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter chronic, acute care and ingredient pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Chronic, Acute Care and Ingredient Pharma Stocks
Chronic, acute care and ingredient pharma stocks reward investors who follow demand trends, order books and margins together. Eris Lifesciences, Alkem Laboratories and Granules India each have a clear plan to grow. Based on the 23 October 2026 close, Eris Lifesciences trades at Rs 1,095.5, Alkem Laboratories at Rs 4,947 and Granules India at Rs 794.75. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these chronic, acute care and ingredient pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track chronic, acute care and ingredient pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are chronic, acute care and ingredient pharma stocks?
Ans. Chronic, acute care and ingredient pharma stocks are listed drug makers that sell chronic and acute care brands in India and supply formulations and ingredients overseas. Their earnings depend on prescriptions, launches, plant quality and export demand. This list looks at three of them, Eris Lifesciences, Alkem Laboratories and Granules India, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which chronic, acute care and ingredient pharma stocks are covered in this list?
Ans. This list covers Eris Lifesciences, Alkem Laboratories and Granules India. Based on the 23 October 2026 close, Eris Lifesciences traded at Rs 1,095.5, Alkem Laboratories at Rs 4,947 and Granules India at Rs 794.75. Their return on equity ranges from 11.7% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 22.9%.
Why do chronic, acute care and ingredient pharma stocks have a strong future roadmap in India?
Ans. Chronic, acute care and ingredient pharma stocks have a strong roadmap in India because growing healthcare access, longer treatment spans and global sourcing of ingredients keep lifting the revenue base. The main drivers are as follows. Chronic therapies. Long-term treatments give repeat demand. Acute care brands. Trusted brands win doctor preference. Ingredient volumes. High-volume molecules support steady output. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Eris Lifesciences performed financially?
Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What risks should investors check before buying chronic, acute care and ingredient pharma stocks?
Ans. Investors should check a few risks before buying chronic, acute care and ingredient pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices can fall in some markets. Input costs. Solvent and raw material prices affect margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of chronic, acute care and ingredient pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
